Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation  Paul J. Martin, Ji Pei,

Slides:



Advertisements
Similar presentations
A Low Effective Dose of Interleukin-7 Is Sufficient to Maintain Cord Blood T Cells Alive without Potentiating Allo-Immune Responses  Laurent Pascal, Bénédicte.
Advertisements

Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.
Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2.
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease  John M. Magenau,
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft- versus-host disease  Christopher J Thoburn, Yuji Miura, Emilie C Bright,
Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft- versus-Host Disease  David A. Knorr, Hongbo Wang, Mukta Aurora,
Vaccination of Children following Allogeneic Stem Cell Transplantation
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or.
Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.
Marco Mielcarek, Kristin A
Activation and Expansion of CD8+ T Effector Cells in Patients with Chronic Graft- versus-Host Disease  Bryan M. Grogan, Laura Tabellini, Barry Storer,
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors  Xupeng.
Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease  Avital.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.
A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease  Paul A. Carpenter,
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome  Caroline Pical-Izard, Roberto.
Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.
Increase of Intermediate Monocytes in Graft-versus-Host Disease: Correlation with MDR1+Th17.1 Levels and the Effect of Prednisolone and 1α,25-Dihydroxyvitamin.
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 
Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates  George E. Georges, Marina.
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation  Joseph Pidala, Marcie Tomblyn, Taiga.
Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.
Lisa A. Palmer, George E. Sale, John I
A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.
Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302  Javier Bolaños-Meade, Juan Wu, Brent R. Logan,
Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results  Joseph Pidala, Jongphil.
Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation  Brandon K.C. Au, Ted A. Gooley, Philippe.
Mesenchymal Stromal Cells Fail to Prevent Acute Graft-versus-Host Disease and Graft Rejection after Dog Leukocyte Antigen-Haploidentical Bone Marrow Transplantation 
Atul Sathe, Sterling B. Ortega, Dorothy I. Mundy, Robert H
Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation  Jan Storek,
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia  Daniella.
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.
A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease  John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic.
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft- versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation 
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS  Aaron T. Gerds, Ted A. Gooley,
Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen  H.
Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,
Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence  Mina Rizk, Madeline.
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
Cord Blood Nucleated Cells Induce Delayed T Cell Alloreactivity
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
Biology of Blood and Marrow Transplantation
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease  Haydar Frangoul, Li.
Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome  Bart L. Scott, Barry Storer,
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Marco Mielcarek, Kristin A
Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2.
Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.
Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal.
Frédéric Baron, Effie W. Petersdorf, Ted Gooley, Brenda M
Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a.
Close Monitoring of Cyclosporine A Concentration as a Means of Preventing Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients  Marietta.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
In Memoriam: E. Donnall Thomas
Optimal Donor Selection: Beyond HLA
Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte.
Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease  John M. Magenau,
Presentation transcript:

Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation  Paul J. Martin, Ji Pei, Ted Gooley, Claudio Anasetti, Frederick R. Appelbaum, Joachim Deeg, John A. Hansen, Richard A. Nash, Effie W. Petersdorf, Rainer Storb, Victor Ghetie, John Schindler, Ellen S. Vitetta  Biology of Blood and Marrow Transplantation  Volume 10, Issue 8, Pages 552-560 (August 2004) DOI: 10.1016/j.bbmt.2004.04.002

Figure 1 Cyclosporine suppresses the expression of CD25 by responder cells in mixed lymphocyte culture. Responder cells were distinguished from stimulator cells with the use of an informative HLA marker, and dead cells were gated out by staining with 7-amino-actinomycin D. Panels A and B show forward light scatter and CD25 staining for cells cultured in the absence (A) or presence (B) of cyclosporine (400 ng/mL) on day 5. The vertical line indicates the distinction between blasts and nonactivated cells, and the horizontal lines indicate the distinctions among the CD25−, CD25-dull, and CD25-bright populations. The percentages of CD25-bright () and CD25-dull (▴) cells were analyzed on days 4 (C and E) and 5 (D and F) both in the whole population (C and D) and separately in blasts identified by high forward light scatter (E and F). Panels C and D also display the total percentage of CD25+ cells (□), whereas panels E and F display the percentage of blasts (□) in the cultures. Biology of Blood and Marrow Transplantation 2004 10, 552-560DOI: (10.1016/j.bbmt.2004.04.002)

Figure 2 Depletion of CD25+ cells on day 4 from a mixed lymphocyte culture in the presence of cyclosporine increased the secondary proliferative response. Cultures were maintained in the absence (A) or presence (B) of cyclosporine (400 ng/mL) and were depleted of CD25 cells (□) or were sham-depleted (). Secondary proliferative responses were tested in the absence of cyclosporine. Data indicate the mean ± SEM 3H-thymidine incorporation in triplicate cultures. Biology of Blood and Marrow Transplantation 2004 10, 552-560DOI: (10.1016/j.bbmt.2004.04.002)